Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy.

Background: Although CD4 cell count monitoring is used to decide when to start antiretroviral therapy in patients with HIV-1 infection, there are no evidence-based recommendations regarding its optimal frequency. It is common practice to monitor every 3 to 6 months, often coupled with viral load monitoring. We developed rules to guide frequency of CD4 cell count monitoring in HIV infection before starting antiretroviral therapy, which we validated retrospectively in patients from the Swiss HIV Cohort Study.Methodology/Principal Findings: We built up two prediction rules ("Snap-shot rule" for a single sample and "Track-shot rule" for multiple determinations) based on a systematic review of published longitudinal analyses of CD4 cell count trajectories. We applied the rules in 2608 untreated patients to classify their 18 061 CD4 counts as either justifiable or superfluous, according to their prior >= 5% or < 5% chance of meeting predetermined thresholds for starting treatment. The percentage of measurements that both rules falsely deemed superfluous never exceeded 5%. Superfluous CD4 determinations represented 4%, 11%, and 39% of all actual determinations for treatment thresholds of 500, 350, and 200x10(6)/L, respectively. The Track-shot rule was only marginally superior to the Snap-shot rule. Both rules lose usefulness for CD4 counts coming near to treatment threshold.Conclusions/Significance: Frequent CD4 count monitoring of patients with CD4 counts well above the threshold for initiating therapy is unlikely to identify patients who require therapy. It appears sufficient to measure CD4 cell count 1 year after a count > 650 for a threshold of 200, > 900 for 350, or > 1150 for 500x10(6)/L, respectively. When CD4 counts fall below these limits, increased monitoring frequency becomes advisable. These rules offer guidance for efficient CD4 monitoring, particularly in resource-limited settings.

Step count is associated with lower nighttime systolic blood pressure and increased dipping.

BACKGROUND: Higher nighttime blood pressure (BP) and the loss of nocturnal dipping of BP are associated with an increased risk for cardiovascular events. However, the determinants of the loss of nocturnal BP dipping are only beginning to be understood. We investigated whether different indicators of physical activity were associated with the loss of nocturnal dipping of BP. METHODS: We conducted a cross-sectional study of 103 patients referred for 24-hour ambulatory monitoring of BP. We measured these patients' step count (SC), active energy expenditure (AEE), and total energy expenditure simultaneously, using actigraphs. RESULTS: In our study population of 103 patients, most of whom were hypertensive, SC and AEE were associated with nighttime systolic BP in univariate (SC, r = -0.28, P < 0.01; AEE, r = -0.20, P = 0.046) and multivariate linear regression analyses (SC, coefficient beta = -5.37, P < 0.001; AEE, coefficient beta = -0.24, P < 0.01). Step count was associated with both systolic (r = 0.23, P = 0.018) and diastolic (r = 0.20, P = 0.045) BP dipping. Nighttime systolic BP decreased progressively across the categories of sedentary, moderately active, and active participants (125mm Hg, 116mm Hg, 112mm Hg, respectively; P = 0.002). The degree of BP dipping of BP increased progressively across the same three categories of activity (respectively 8.9%, 14.6%, and 18.6%, P = 0.002, for systolic BP and respectively 12.8%, 18.1%, and 22.2%, P = 0.006, for diastolic BP). CONCLUSIONS: Step count is continuously associated with nighttime systolic BP and with the degree of BP dipping independently of 24-hour mean BP. The combined use of an actigraph for measuring indicators of physical activity and a device for 24-hour measurement of ambulatory BP may help identify patients at increased risk for cardiovascular events in whom increased physical activity toward higher target levels may be recommended.

Consumer Advisory Bulletin, Fair Debt Collection: Know Your Rights, March 2007

The Attorney General’s Consumer Protection Division receives hundreds of calls and consumer complaints every year. Follow these tips to avoid unexpected expense and disappointments. This record is about: Fair Debt Collection: Know Your Rights

Nouvelle collection des mémoires pour servir à l'histoire de France. 2, Mémoires de messire François Duval, marquis de Fontenay-Mareuil

Comprend : Mémoires concernant les affaires de France sous la régence de Marie de Médicis ; Mémoires du duc de Rohan

Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.

OBJECTIVES: To investigate prevalence of transmitted drug-resistant human immunodeficiency virus (TDR) and factors associated with TDR and to compare virological and CD4 count response to combination antiretroviral therapy. METHODS: In this study, 525 mostly chronically infected EuroSIDA patients were included who had genotypic resistance tests performed on plasma samples collected while antiretroviral therapy naive. TDR was defined as at least one resistance mutation from a list proposed for genotypic TDR surveillance. Multivariable logistic regression was used to analyze factors associated with detection of TDR, with virological (viral load<500 copies/mL) and CD4 count response (>or=50% increase) to combination antiretroviral therapy at months 6-12. RESULTS: The overall prevalence of TDR was 11.4%, which was stable over 1996-2004. There were no significant differences in virological suppression (those resistant to at least one drug prescribed versus susceptible), adjusted odds ratio: 0.68 (95% confidence interval: 0.27 to 1.71; P=0.408) or CD4 count response, adjusted odds ratio: 1.65 (95% confidence interval: 0.73 to 3.73; P=0.231). CONCLUSIONS: Prevalence of TDR in antiretroviral-naive patients was found to be in line with other European studies. No significant differences were found in virological and CD4 count response after initiation of first-line combination antiretroviral therapy between resistant and susceptible patients, possibly due to the small number of patients with resistance and consequently low power.

[Collection Jules Beau. Photographie sportive] : T. 13. Année 1900 / Jules Beau

Donateur : Touring-Club de France

[Collection Jules Beau. Photographie sportive] : T. 15. Année 1901 / Jules Beau

Donateur : Touring-Club de France

[Collection Jules Beau. Photographie sportive] : T. 34. Années 1907 et 1908 / Jules Beau

Donateur : Touring-Club de France

Catalogue of type specimens of invertebrates in the collection of the Instituto Nacional de Pesquisas da Amazônia, Manaus, Brazil. II. Hexapoda: Collembola, Diplura, Archaeognatha, Ephemeroptera and Blattaria

A catalogue of type specimens of Collembola, Diplura, Archaeognatha, Ephemeroptera, and Blattaria deposited in the Invertebrate Collection of the Instituto Nacional de Pesquisas da Amazônia (INPA), Manaus, Brazil, is presented and updated to June, 2007. It contains a total of 22 holotypes and 18 lots of paratypes of 22 species of Collembola; one holotype and one paratype of one species of Diplura; four holotypes and four paratypes of four species of Archaeognatha; 10 holotypes and thirteen lots of paratypes of 11 species of Ephemeroptera; and one holotype and two lots of paratypes of one species of Blattaria. Specific names are listed alphabetically within family, followed by bibliographical citation, original genus name, status of type, collection number and locality data.

Catalogue of type specimens of the Collection of Invertebrates of Instituto Nacional de Pesquisas da Amazônia, Manaus, Brazil. III. Hexapoda: Isoptera, Mantodea, Mecoptera, Orthoptera, Plecoptera, Trichoptera and Zoraptera

A catalogue of the type specimens of Isoptera, Mantodea, Mecoptera, Orthoptera, Plecoptera, Trichoptera, and Zoraptera deposited in the Invertebrate Collection of the Instituto Nacional de Pesquisas da Amazônia (INPA), Manaus, Brazil, is presented and updated to December, 2007. A total of eight holotypes and seven lots of paratypes of nine species of Isoptera; three holotypes and one paratype of three species of Mantodea; five holotypes and five lots of paratypes of five species of Mecoptera; eight holotypes and five lots of paratypes of eleven species of Orthoptera; three holotypes, three neotypes and two lots of paratypes of seven species of Plecoptera; six holotypes and seven lots of paratypes of ten species of Trichoptera; and two holotypes and three lots of paratypes of three species of Zoraptera, are listed. Specific names are listed alphabetically within the family, followed by bibliographic citation, original genus name, status of type, collection number, locality data and remarks when appropriate.